Acetylon Pharmaceuticals has received US patent covering fundamental composition of matter claims of the selective HDAC6 inhibitor, ACY-1215.
ACY-1215T is at present being investigated in human trials to treat multiple myeloma.
Acetylon chief executive officer Walter Ogier said, "Given the widespread interest in the development of selective histone deacetylase (HDAC) inhibitors, it is important for Acetylon to demonstrate that we have unique, patentable drug candidates within a competitive composition-of-matter field of intellectual property."
In September 2011, the patent application was issued prioritized examination status under the provisions of the new America Invents Act, the company said.
The Act provides for prioritized fast track examination of patent applications that satisfy specific limitations regarding the number and type of examined claims.
Acetylon chemistry and manufacturing vice president John H van Duzer said, "Acquiring U.S. patent protection for ACY-1215 is a major step for Acetylon as the company continues to explore the use of this drug in the treatment of multiple myeloma."
